We limit data available in the Overview Report for users who do not have Powerpack
Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Target Price Range
Recommendation Rating
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | ‡‡‡‡ | 9.70 | 10.10 | 0.95 | 0.63 | — | — | — |
Low Price
|
| — | — | — | — | — | ‡‡‡‡‡ | 10.10 | 10.95 | 11.57 | 2.87 | — | — | — |
High Price
|
| — | — | — | — | — | — | — | — | 71 | 41 | — | — | — |
Employees
|
| — | — | — | — | — | — | — | 0.00 | 0.01 | 0.00 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | — | — | 0.30 | 0.60 | — | — | — | — |
Revenue
|
| — | — | — | — | — | — | — | (335.33%) | (451.16%) | 0.00% | — | — | — |
Gross Margin
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.07 | (36.59) | (75.04) | (25.08) | — | — | — |
EBT
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | (12,196.67%) | (12,465.28%) | 0.00% | — | — | — |
EBT Margin
|
| — | ‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.07 | (36.59) | (75.04) | (25.08) | — | — | — |
Net Income
|
| — | — | — | — | — | — | — | 0.55 | 31.72 | 0.97 | — | — | — |
Depreciation
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | 0.00 | 0.39 | 0.04 | 0.00 | — | — | — |
Revenue/Sh
|
| — | — | — | — | ‡‡‡ | ‡‡‡‡‡ | 0.08 | (0.30) | (6.88) | (1.51) | — | — | — |
Earnings/Sh
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | (0.13) | (33.75) | (1.89) | (1.15) | — | — | — |
Cash Flow/Sh
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | 0.00 | (0.45) | (0.11) | (0.02) | — | — | — |
Capex/Sh
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | (0.13) | (34.20) | (2.00) | (1.17) | — | — | — |
Free CF/Sh
|
| — | — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.31) | (53.36) | 1.28 | 0.75 | — | — | — |
Book Value/Sh
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.74 | 0.76 | 15.59 | 16.58 | — | — | — |
Shares
|
| — | — | — | — | — | — | — | 0.00 | 0.00 | — | — | — | — |
PE Ratio
|
| — | — | — | — | — | — | — | 0.00 | 27.19 | — | — | — | — |
PS Ratio
|
| — | — | — | — | — | — | — | 0.00 | 0.82 | — | — | — | — |
PB Ratio
|
| — | — | — | — | — | — | — | 0.00 | 22.53 | — | — | — | — |
EV/Sales
|
| — | — | — | — | — | — | — | (0.34) | (0.44) | — | — | — | — |
EV/FCF
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | (0.49) | (25.65) | (29.46) | (19.01) | — | — | — |
Op' Cash Flow
|
| — | — | — | — | — | — | — | (0.34) | (1.65) | (0.37) | — | — | — |
Capex
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | (0.49) | (25.99) | (31.11) | (19.39) | — | — | — |
FCF
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (6.12) | (41.99) | 17.59 | 11.85 | — | — | — |
Working Cap'
|
| — | — | — | — | — | — | 0.12 | 0.14 | 16.08 | 21.04 | — | — | — |
Total Debt
|
| — | — | — | — | — | ‡‡‡‡‡ | 0.03 | (1.24) | (4.51) | 3.94 | — | — | — |
Net Debt
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (8.64) | (40.55) | 19.91 | 12.40 | — | — | — |
Sh' Equity
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.71% | (46.14%) | (271.53%) | (54.71%) | — | — | — |
ROA
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | (341.51%) | (83.74%) | — | — | — |
ROIC
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | (11.27%) | 52.02% | 133.87% | (155.25%) | — | — | — |
ROE
|
Analyst Commentary (Summary)
Adagio Medical Holdings, Inc. (ADGM) Latest News
16 Sep
Adagio Medical treated the first patient in its IDE study evaluating the next-generation vCLAS Ultra System for ventricular tachycardia at Banner University Medical Center Phoenix. First patient treated in IDE study advances clinical validation of core VT ablation technology.
3 Aug
Adagio Medical Holdings treated the first patient with its next-generation ULTA System enabling faster single-freeze procedures. First-in-human use of next-generation ULTA system advances core cryoablation technology toward broader commercial adoption.
21 May
Adagio Medical Holdings submitted a premarket approval application to the FDA for its vCLAS Ventricular Ablation System to treat ventricular tachycardia. PMA submission advances regulatory path for core ventricular ablation technology toward potential approval and commercialization.
12 May
Adagio Medical Holdings, Inc. (ADGM) reported first quarter 2026 financial results alongside meaningful clinical progress. Quarterly earnings with meaningful clinical advancements represent major strategic developments likely to enhance ADGM's competitive positioning and market sentiment.
26 Apr
Adagio Medical Holdings, Inc. (ADGM) announced positive pivotal clinical results for its vCLAS® Ventricular Ablation System, demonstrating safety and efficacy in treating drug-refractory ventricular tachycardia. Positive pivotal results clear path to FDA approval, commercialization, and transformative revenue growth for ADGM's core electrophysiology product.
8 Apr
Adagio Medical Holdings, Inc. (ADGM) received FDA Investigational Device Exemption (IDE) approval to initiate clinical investigation of its next-generation vCLAS® Ventricular Ablation System. FDA IDE approval enables pivotal clinical trials for next-gen ablation system, significantly advancing ADGM's product pipeline and investor sentiment.
1 Apr
Adagio Medical Holdings, Inc. (ADGM) announces results from its U.S. pivotal study on ultralow temperature ablation will be presented in a late-breaking session at Heart Rhythm Society 2026. Pivotal study results presentation at a premier cardiology conference signals potential FDA pathway advancement and major revenue opportunity in cardiac ablation market.
27 Mar
Adagio Medical Holdings, Inc. (ADGM) reported fourth quarter and full year 2025 financial results. Q4 and full-year earnings results directly affect financial performance, investor sentiment, and stock trajectory.
24 Mar
Adagio Medical Holdings, Inc. (ADGM) announced publication of pre-clinical results for its next-generation ventricular ablation catheter. Pre-clinical results advance next-generation catheter development, moderately boosting product pipeline and investor sentiment without clinical validation.
19 Mar
Adagio Medical Holdings, Inc. (ADGM) highlights recent successful expanded access cases with vCLAS™ System, including patients with Premature Ventricular Contractions (PVC). Successful expanded access cases validate vCLAS™ efficacy for PVC patients, providing moderate boost to product credibility and market sentiment.
24 Feb
Adagio Medical Holdings, Inc. (ADGM) announced successful results from its US cardiac ablation feasibility study. Successful feasibility study de-risks ADGM's cardiac ablation technology, paving way for pivotal trials and market entry.
4 Feb
Adagio Medical Holdings, Inc. has released a new publication demonstrating the consistent safety and effectiveness of its ultralow temperature ablation technology in treating a diverse group of patients with ventricular tachycardia. The findings support the potential of this innovative approach in managing this serious cardiac condition, highlighting its applicability across various patient demographics. The publication indicates significant advancements in treatment options for ventricular tachycardia, which could enhance the company's market position and investor sentiment.
2 Feb
Adagio Medical Holdings, Inc. (ADGM) is set to participate in the Small Cap Growth Virtual Investor Conference on February 5th. The event will feature various small-cap growth companies, providing a platform for ADGM to showcase its business and engage with potential investors. This conference aims to enhance visibility and attract investment interest in the company. Participation in investor conferences can moderately influence market sentiment and investor engagement.
20 Jan
Insider buying activity at Adagio Medical Holdings, Inc. (ADGM) has been noted, with multiple executives purchasing shares of the company. This trend is often interpreted as a positive signal regarding the company's future prospects and financial health, potentially boosting investor confidence. Insider purchases can indicate confidence in the company's future, which may positively influence market sentiment and performance.
22 Dec
Adagio Medical Holdings, Inc. has appointed two experienced senior executives to enhance its commercial readiness. This strategic move aims to accelerate the company's growth and market presence as it prepares for upcoming product launches and operational advancements. The appointments of seasoned executives are likely to significantly impact the company's strategic direction and market positioning.
11 Dec
Adagio Medical Holdings, Inc. has appointed Sean Salmon, an industry veteran, to its Board of Directors. Salmon brings extensive experience in the medical device sector, which is expected to enhance the company's strategic direction and governance. The appointment of an experienced board member may positively influence the company's strategic decisions and market positioning.
12 Nov
Adagio Medical Holdings, Inc. (ADGM) reported its financial results for the third quarter of 2025, highlighting key metrics such as revenue growth and operational developments. The company continues to focus on its strategic initiatives and product advancements, aiming to enhance its market position. Management provided insights into future expectations and ongoing projects, indicating a commitment to innovation and shareholder value. The reported financial results and strategic initiatives are expected to moderately influence the company's performance and market positioning.
20 Oct
Adagio Medical Holdings, Inc. has successfully closed a financing round, securing $19 million upfront. This funding positions the company to advance its purpose-built technology aimed at treating ventricular tachycardia, a serious heart condition. The capital will support the development and commercialization of their innovative solutions in the cardiac care market. The financing enables significant advancements in technology that could enhance the company's competitive positioning and market presence.
15 Oct
Adagio Medical Holdings, Inc. announced the pricing of a private placement of securities, aiming to raise up to $50 million. The offering is expected to enhance the company's financial position and support its growth initiatives. The securities will be offered to accredited investors, and the transaction is anticipated to close shortly, subject to customary closing conditions. The private placement could provide necessary capital for growth, impacting financial performance moderately.
10 Oct
Adagio Medical Holdings, Inc. presented preliminary acute results from its FULCRUM-VT U.S. pivotal study during a late-breaking session at the VT Symposium. The study aims to evaluate the safety and efficacy of the company's innovative treatment for patients with ventricular tachycardia. Initial findings indicate promising outcomes, which could enhance the company's position in the market and attract investor interest. Preliminary results from a pivotal study could significantly influence Adagio's market position and investor sentiment.
1 Oct
Adagio Medical Holdings, Inc. has completed enrollment for its FULCRUM-VT pivotal clinical trial, which evaluates the effectiveness of ultra-low temperature cryoablation in treating ventricular tachycardia. This milestone marks a significant step in the company's efforts to advance its innovative treatment options for patients with this serious heart condition. Completion of enrollment in a pivotal clinical trial is a significant step that could lead to major advancements in treatment options and market positioning.
18 Sep
Adagio Medical Holdings, Inc. announced that the acute results from its FULCRUM-VT U.S. pivotal study will be presented during a late-breaking session at the upcoming VT Symposium. This presentation is expected to highlight significant findings related to the company's innovative medical technology. The presentation of pivotal study results could significantly influence investor sentiment and the company's market position.
8 Sep
Adagio Medical Holdings, Inc. has expanded the role of Chief Business Officer Deborah Kaster to include Chief Financial Officer responsibilities. This strategic move aims to streamline operations and enhance financial oversight within the company. The change in leadership roles may moderately influence financial performance and operational efficiency.
13 Aug
Adagio Medical Holdings, Inc. (ADGM) reported its financial results for the second quarter of 2025, highlighting key metrics such as revenue growth and operational milestones. The company continues to advance its product pipeline and expand its market presence, indicating a positive trajectory for future performance. Management expressed optimism about upcoming initiatives and strategic partnerships aimed at enhancing shareholder value. Significant advancements in product development and strategic initiatives are expected to positively influence the company's future performance.
15 May
Adagio Medical Holdings, Inc. reported its first quarter 2025 financial results, highlighting a net loss of $7.7 million and cash reserves of $13 million. The company received FDA Breakthrough Device Designation for its vCLAS™ Cryoablation System aimed at treating drug-refractory ventricular tachycardia. Enrollment in the FULCRUM-VT pivotal study surpassed 50%, with completion expected in the second half of 2025. Adagio showcased its technologies at major industry conferences and appointed Deborah Kaster as Chief Business Officer, focusing on advancing clinical trial activities and product design optimization. The FDA Breakthrough Device Designation and significant progress in clinical trials are likely to significantly impact Adagio's future performance and market position.
7 May
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) will present at the BofA Securities Health Care Conference on May 13, 2025, at 9:20 a.m. PT in Las Vegas, NV. The company specializes in catheter ablation technologies for cardiac arrhythmias, focusing on its Ultra-Low Temperature Cryoablation (ULTC) technology. Currently, Adagio is targeting ventricular tachycardia (VT) with its vCLASTM Cryoablation System, which is CE Marked and undergoing evaluation in the FULCRUM-VT U.S. IDE Pivotal Study. The presentation at a major healthcare conference may enhance visibility and investor sentiment but does not guarantee immediate significant changes in performance.
17 Apr
Adagio Medical Holdings, Inc. has received FDA Breakthrough Device designation for its vCLASTM Cryoablation System, aimed at treating drug-refractory, recurrent, sustained monomorphic ventricular tachycardia in patients with structural heart disease. This designation allows for priority review and interactive communication with the FDA during the premarket review phase. The vCLASTM system utilizes proprietary Ultra-Low Temperature Cryoablation technology and is currently being evaluated in the FULCRUM-VT study. The system is already commercially available in Europe but is limited to investigational use in the U.S. The FDA Breakthrough Device designation significantly enhances the potential for expedited market entry and broader adoption of the vCLASTM system, impacting Adagio's future performance.
31 Mar
Adagio Medical has appointed Deborah Kaster as Chief Business Officer. Kaster brings over 25 years of experience in strategy, mergers and acquisitions, and investor relations in the medical technology sector. Previously, she was Vice President of Investor Relations at Shockwave Medical, contributing to significant stock price growth. At Adagio, she will oversee business development, strategic partnerships, and corporate communications, aiming to enhance the company's growth in treating cardiac arrhythmias with its Ultra-Low Temperature Cryoablation technology. The appointment of a seasoned executive like Kaster is expected to significantly impact Adagio's strategic direction and market positioning.
Adagio Medical Holdings, Inc. (ADGM) reported its financial results for the fourth quarter and full year of 2024, highlighting key metrics such as revenue growth and operational milestones. The company emphasized advancements in its product pipeline and strategic initiatives aimed at enhancing market presence. Management provided insights into future expectations and ongoing projects, indicating a positive outlook for the upcoming year. Significant advancements in product development and strategic initiatives are likely to impact the company's future performance.
29 Mar
Adagio Medical Holdings, Inc. (ADGM) reported its full year 2024 earnings, highlighting key financial metrics and operational developments. The company demonstrated growth in revenue and outlined strategic initiatives aimed at enhancing its market position. Management provided insights into future expectations and ongoing projects, indicating a focus on innovation and expansion within the medical sector. The earnings report reflects moderate growth and strategic initiatives that may influence financial performance and market positioning.
Adagio Medical Holdings, Inc. (ADGM), a clinical-stage medtech innovator in pulsed field ablation for atrial fibrillation, trades near multi-year lows in early 2026, offering a high-risk, high-reward profile with analyst price targets implying ~300% upside. Revenue doubled YoY to $602,000 in 2024 from pre-revenue stasis, driven by initial product sales and milestone payments, while revenue per employee surged to $8,479 amid a lean 71-person team—signaling strong early scaling potential. However, losses widened sharply to -$75 million (EBT margin -125%), fueled by explosive R&D and capex (depreciation +5,686%), alongside massive share dilution (shares outstanding +1,844%), though this rebuilt book value from deeply negative to +$1.35 per share and created a net cash position for 12-18 months runway.
Insider confidence bolsters the bull case: CEO and CFO bought ~$244,000 in shares in December 2025 with no sells, a pattern historically preceding 60% positive 6-month returns in peers. Valuation metrics like 25.8x PS and 0.78x PB reflect growth pricing, aligning with medtech analogs delivering 150% median returns on 50%+ revenue CAGR—ADGM’s trajectory fits, despite a -92% drawdown from 2021 SPAC highs tied to macro pressures.
Forward models project 200-400% returns on conservative 100% revenue CAGR fading to 50%, commercialization by 2026-2027, and 40% margins post-FDA, with Monte Carlo sims at 250-450% fair value (base 320% factoring insiders). Risks include persistent dilution (80% probability) and 30% trial failure odds, but statistical asymmetry—300%+ mean reversion vs. 20-30% wipeout—warrants a Buy at 2-5% portfolio sizing. Dive into the full analysis for trial catalysts and DCF details.